Metastatic prostate cancer: Chemotherapy use and survival have increased in recent years

Key clinical point: Use of chemotherapy and survival has increased in contemporary patients with de novo metastatic prostate cancer vs historical patients.

Major finding: The rates of chemotherapy were not significantly different between 2004 and 2013 (P = .3). The chemotherapy rates increased from 17.2% to 24.7% between 2014 and 2016 (P = .04). After propensity score matching, the median overall survival was significantly longer in contemporary vs. historical patients (not reached vs 25 months; adjusted hazard ratio [aHR], 0.55; P < .001). Cancer-specific mortality also improved in contemporary patients (not reached vs. 26 months; aHR, 0.55; P < .001).

Study details: A retrospective study of 19,913 patients who had de novo metastatic prostate cancer between 2004 and 2016, divided between historical (2004-2013) and contemporary (2014-2016).

Disclosures: No funding source was identified for this work. The authors had no competing interests.

Source: Hoeh B et al. Prostate. 2021 Sep 15. doi: 10.1002/pros.24235.

Key clinical point: Use of chemotherapy and survival has increased in contemporary patients with de novo metastatic prostate cancer vs historical patients.

Major finding: The rates of chemotherapy were not significantly different between 2004 and 2013 (P = .3). The chemotherapy rates increased from 17.2% to 24.7% between 2014 and 2016 (P = .04). After propensity score matching, the median overall survival was significantly longer in contemporary vs. historical patients (not reached vs 25 months; adjusted hazard ratio [aHR], 0.55; P < .001). Cancer-specific mortality also improved in contemporary patients (not reached vs. 26 months; aHR, 0.55; P < .001).

Study details: A retrospective study of 19,913 patients who had de novo metastatic prostate cancer between 2004 and 2016, divided between historical (2004-2013) and contemporary (2014-2016).

Disclosures: No funding source was identified for this work. The authors had no competing interests.

Source: Hoeh B et al. Prostate. 2021 Sep 15. doi: 10.1002/pros.24235.

Key clinical point: Use of chemotherapy and survival has increased in contemporary patients with de novo metastatic prostate cancer vs historical patients.

Major finding: The rates of chemotherapy were not significantly different between 2004 and 2013 (P = .3). The chemotherapy rates increased from 17.2% to 24.7% between 2014 and 2016 (P = .04). After propensity score matching, the median overall survival was significantly longer in contemporary vs. historical patients (not reached vs 25 months; adjusted hazard ratio [aHR], 0.55; P < .001). Cancer-specific mortality also improved in contemporary patients (not reached vs. 26 months; aHR, 0.55; P < .001).

Study details: A retrospective study of 19,913 patients who had de novo metastatic prostate cancer between 2004 and 2016, divided between historical (2004-2013) and contemporary (2014-2016).

Disclosures: No funding source was identified for this work. The authors had no competing interests.

Source: Hoeh B et al. Prostate. 2021 Sep 15. doi: 10.1002/pros.24235.